Literature DB >> 21448644

Fatigue and severity of rheumatoid arthritis in Moroccan patients.

Yousra Ibn Yacoub1, Bouchra Amine, Assia Laatiris, Fahd Wafki, Fatima Znat, Najia Hajjaj-Hassouni.   

Abstract

The aim of this study was to assess fatigue aspects in Moroccan patients with rheumatoid arthritis (RA) and its relationships with disease-specific variables especially parameters of functional and structural severity. A total of 248 patients with RA were included. Patients' and disease characteristics were identified. Disease activity was measured clinically using physical examination, biologically and by the disease activity scores (DAS28). Radiographs were evaluated by using Sharp's method as modified by van der Heijde. Functional disability was measured by using the Moroccan version of Health Assessment Questionnaire (HAQ). Immunological abnormalities and treatment (doses and duration) were identified. Fatigue was evaluated by using a 0-100 visual analogue scale (VAS fatigue) and the multidimensional assessment of fatigue (MAF). Quality of life (QoL) was assessed using the Arabic version of the generic instrument SF-36. The mean age of patients was 47.5 ± 11.7 years [25-72]; 37.5% of patients had a high activity of disease and 11.3% were in remission. The mean Sharp score was 107.13 ± 91, and the mean score of HAQ was 1.40 ± 0.63. All domains of QoL were deteriorated; 89.51% of our patients experienced fatigue. The mean total score of MAF was 30.21 ± 11.32. A low level of education, low socioeconomic status, atlantoaxial subluxation, hip involvement, the presence of a Sjögren syndrome, and cigarette smoking had a negative impact on fatigue scores. The severity of fatigue was correlated with the duration of RA, the intensity of joint pain, the activity of disease, the importance of structural damage, the degree of functional impairment, and the rate of anti-cyclic citrullinated protein (CCP) antibodies (P < 0.05). Patients receiving methotrexate had better scores of fatigue. Also, severity of fatigue was correlated with the deterioration of all domains of QoL. Fatigue is a major issue for our patients with RA and must be included in the routine assessment of patients. In our sample, fatigue appears to be related to disease activity, functional disability, structural damage, and immunological status and had a negative impact on QoL.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21448644     DOI: 10.1007/s00296-011-1876-0

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  35 in total

1.  2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative.

Authors:  Daniel Aletaha; Tuhina Neogi; Alan J Silman; Julia Funovits; David T Felson; Clifton O Bingham; Neal S Birnbaum; Gerd R Burmester; Vivian P Bykerk; Marc D Cohen; Bernard Combe; Karen H Costenbader; Maxime Dougados; Paul Emery; Gianfranco Ferraccioli; Johanna M W Hazes; Kathryn Hobbs; Tom W J Huizinga; Arthur Kavanaugh; Jonathan Kay; Tore K Kvien; Timothy Laing; Philip Mease; Henri A Ménard; Larry W Moreland; Raymond L Naden; Theodore Pincus; Josef S Smolen; Ewa Stanislawska-Biernat; Deborah Symmons; Paul P Tak; Katherine S Upchurch; Jirí Vencovsky; Frederick Wolfe; Gillian Hawker
Journal:  Ann Rheum Dis       Date:  2010-09       Impact factor: 19.103

Review 2.  Epidemiology of rheumatoid arthritis: determinants of onset, persistence and outcome.

Authors:  Deborah P M Symmons
Journal:  Best Pract Res Clin Rheumatol       Date:  2002-12       Impact factor: 4.098

3.  Health-related quality of life in early rheumatoid arthritis: impact of disease and treatment response.

Authors:  Mark Kosinski; Sara C Kujawski; Richard Martin; Lee A Wanke; Mary C Buatti; John E Ware; Eleanor M Perfetto
Journal:  Am J Manag Care       Date:  2002-03       Impact factor: 2.229

4.  Fatigue in rheumatoid arthritis: the role of self-efficacy and problematic social support.

Authors:  R P Riemsma; J J Rasker; E Taal; E N Griep; J M Wouters; O Wiegman
Journal:  Br J Rheumatol       Date:  1998-10

5.  Correlation of anti-cyclic citrullinated antibody with hand joint erosion score in rheumatoid arthritis patients.

Authors:  Hyun Hee Kim; Jihun Kim; Sung-Hoon Park; Seong-Kyu Kim; Ok-Dong Kim; Jung-Yoon Choe
Journal:  Korean J Intern Med       Date:  2010-06-01       Impact factor: 3.165

6.  The prevalence and meaning of fatigue in rheumatic disease.

Authors:  F Wolfe; D J Hawley; K Wilson
Journal:  J Rheumatol       Date:  1996-08       Impact factor: 4.666

7.  Predictors of subjective fatigue among individuals with rheumatoid arthritis.

Authors:  B A Huyser; J C Parker; R Thoreson; K L Smarr; J C Johnson; R Hoffman
Journal:  Arthritis Rheum       Date:  1998-12

8.  Psychometric evaluation of a Moroccan version of health assessment questionnaire for use in Moroccan patients with rheumatoid arthritis.

Authors:  Fatima Ezzahra Abourazzak; Karima Benbouazza; Bouchra Amine; Rachid Bahiri; Noufissa Lazrak; Fatiha Bzami; Imane Jroundi; Redouane Abouqal; Francis Guillemin; Najia Hajjaj-Hassouni
Journal:  Rheumatol Int       Date:  2008-06-06       Impact factor: 2.631

9.  Comparison of self-reported fatigue in rheumatoid arthritis and controls.

Authors:  B L Belza
Journal:  J Rheumatol       Date:  1995-04       Impact factor: 4.666

10.  The health-related quality of life in rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis: a comparison with a selected sample of healthy people.

Authors:  Fausto Salaffi; Marina Carotti; Stefania Gasparini; Michele Intorcia; Walter Grassi
Journal:  Health Qual Life Outcomes       Date:  2009-03-18       Impact factor: 3.186

View more
  8 in total

1.  Rheumatoid factor and antibodies against citrullinated peptides in Moroccan patients with rheumatoid arthritis: association with disease parameters and quality of life.

Authors:  Yousra Ibn Yacoub; Bouchra Amine; Assia Laatiris; Najia Hajjaj-Hassouni
Journal:  Clin Rheumatol       Date:  2011-08-04       Impact factor: 2.980

2.  Sociodemographic factors associated with functional disability in outpatients with rheumatoid arthritis in Southwest China.

Authors:  Shangping Zhao; Yanling Chen; Hong Chen
Journal:  Clin Rheumatol       Date:  2015-02-18       Impact factor: 2.980

3.  One-year direct costs of biological therapy in rheumatoid arthritis and its predictive factors: data from the Moroccan RBSMR registry.

Authors:  Safaa Fellous; Hanan Rkain; Samir Ahid; Redouane Abouqal; Latifa Tahiri; Ihsane Hmamouchi; Lahsen Achemlal; Imane El Bouchti; Abdellah El Maghraoui; Imad Ghozlani; Hasna Hassikou; Taoufik Harzy; Linda Ichchou; Ouafa Mkinsi; Radouane Niamane; Rachid Bahiri; Fadoua Allali
Journal:  Rheumatol Int       Date:  2021-01-02       Impact factor: 2.631

4.  Health-related quality of life in Moroccan patients with rheumatoid arthritis.

Authors:  Yousra Ibn Yacoub; Bouchra Amine; Assia Laatiris; Najia Hajjaj-Hassouni
Journal:  Clin Rheumatol       Date:  2012-08-18       Impact factor: 2.980

5.  A biopsychosocial network model of fatigue in rheumatoid arthritis: a systematic review.

Authors:  Rinie Geenen; Emma Dures
Journal:  Rheumatology (Oxford)       Date:  2019-11-01       Impact factor: 7.580

Review 6.  A structured literature review of the burden of illness and unmet needs in patients with rheumatoid arthritis: a current perspective.

Authors:  Peter C Taylor; Adam Moore; Radu Vasilescu; Jose Alvir; Miriam Tarallo
Journal:  Rheumatol Int       Date:  2016-01-08       Impact factor: 2.631

7.  Shared Medical and Environmental Risk Factors in Dry Eye Syndrome, Sjogren's Syndrome, and B-Cell Non-Hodgkin Lymphoma: A Case-Control Study.

Authors:  Hadas Ben-Eli; Doron J Aframian; Eldad Ben-Chetrit; Dror Mevorach; Geffen Kleinstern; Ora Paltiel; Abraham Solomon
Journal:  J Immunol Res       Date:  2019-01-21       Impact factor: 4.818

8.  Fatigue is cross-sectionally not associated with objective assessments of inflammation, but changes in fatigue are associated with changes of disease activity assessments during biologic treatment of patients with established rheumatoid arthritis.

Authors:  Hilde Berner Hammer; Brigitte Michelsen; Joe Sexton; Till Uhlig; Sella A Provan
Journal:  Clin Rheumatol       Date:  2020-10-11       Impact factor: 2.980

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.